Skip to main content
. 2016 Jan 15;5(4):728–738. doi: 10.1002/cam4.597

Table 2.

Crude and age‐standardized rates per 100,000 persons of pathology‐confirmed hematologic malignancies reported to NCR‐SA per 100,000 by race and gender at age ≥15 years for 2000–2006

Gender Hematologic malignancy Black White Coloured Asian/Indian Alla
N Crude ASR15+ N Crude ASR15+ N Crude ASR15+ N Crude ASR15+ N Crude ASR15+
Females Leukemiab 758 0.85 0.97 390 2.78 2.39 123 1.20 1.40 59 1,84 1,84 1394 1.19 1.32
Myelomac 456 0.51 0.68 191 1.36 1.06 94 0.89 1.23 15 0,47 0,55 788 0.67 0.83
HLd 366 0.41 0.42 229 1.63 1.69 85 0.80 0.82 44 1,38 1,36 749 0.64 0.65
NHLe 1867 2.09 2.26 1334 9.50 7.60 384 3.63 4.60 120 3,75 4,06 3871 3.30 3.65
Males Leukemiab 864 1.06 1.32 568 4.32 3.86 162 1.70 2.26 71 2,31 2,40 1737 1.62 2.01
Myelomac 432 0.53 0.83 196 1.49 1.23 77 0.81 1.24 17 0,55 0,72 755 0.70 1.00
HLd 516 0.63 0.63 305 2.32 2.32 114 1.20 1.22 61 1,99 2,10 1041 0.97 0.99
NHLe 1975 2.43 2.89 1509 11.48 9.85 464 4.87 6.57 125 4,07 4,69 4281 4.00 4.98

ASR15+ – age‐standardized rates, truncated to ages ≥15 years. HL, Hodgkin lymphoma; NHL, Non‐Hodgkin lymphoma; ICD‐O‐3, International Classification of Diseases for Oncology, third edition.

a

Includes cases with unknown population group.

b

Leukemia – ICD‐O‐3 morphology codes: 9826, 9835–9836, 9820, 9832–9834, 9940, 9840, 9861, 9865–9867, 9869, 9871–9874, 9895–9897, 9898, 9910–9911, 9920, 9891, 9863, 9875–9876, 9945–9946, 9860, 9930, 9801, 9805–9809, 9931, 9733, 9742, 9800, 9831, 9870, 9948, 9963–9964. Also includes 9811–9818, 9837, 9823, and 9827 if site code C42.0, C42.1 or C42.4

c

Myeloma – ICD‐O‐3 morphology codes: 9731–9732, 9734.

d

Hodgkin lymphoma – ICD‐O‐3 morphology codes: 9650–9667.

e

Non‐Hodgkin lymphoma – ICD‐O‐3 morphology codes: 9590–9597, 9670–9671, 9673, 9675, 9678–9680, 9684, 9687–9691, 9695, 9698–9702, 9705, 9708–9709, 9712, 9714–9719, 9724–9729, 9735, 9737–9738. For sites other than C42.0, C42.1, and C42.4 also includes 9811–9818, 9823, 9827, 9837.